M. Malaise

Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population (2008)

Vander Cruyssen, Bert, WESTHOVENS, R, DUREZ, P, VAN DEN BOSCH, FILIP, Mielants, Herman, DE CLERCK, L, ...

A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip (2007)

Geusens, P, Malaise, M, De Clerck, L, Raeman, F, ...

OBJECTIVE: To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare. METHODS: In this 24-week, prospective, randomised,...

A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip (2007)

Luyten, F. P., GEUSENS, Piet, Malaise, M., De Clerck, L., Westhovens, R., Raeman, F., ...

Objective: To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare. Methods: In this 24-week, prospective, randomised,...

A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip (2007)

Luyten, F. P., GEUSENS, Piet, Malaise, M., De Clerck, L., Westhovens, R., Raeman, F., ...

Objective: To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare. Methods: In this 24-week, prospective, randomised,...

A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip (2007)

LUYTEN, FP, GEUSENS, P, MALAISE, M, DE CLERCK, L, WESTHOVENS, R, RAEMAN, F, ...

Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition (2006)

Vander Cruyssen, Bert, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, Mielants, Herman, DE CLERCK, L, ...

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity (2006)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, ...

Healthcare consumption and direct costs of rheumatoid arthritis in Belgium (2005)

Boonen, A, Verbruggen, L, Durez, P, De Clerck, L, Malaise, M, ...

The aim of this study was to compare the socioeconomic consequences of early and late rheumatoid arthritis in Belgium and to assess the patient out-of-pocket contributions. This multicentre...

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study (2005)

Corluy, L, Veys, E M, De Clerck, L, Peretz, A, ...

OBJECTIVES: To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. METHODS: Patients...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)

Cruyssen, B, Van Looy, S, Wyns, B, Westhovens, R, Durez, P, Malaise, M, ...

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3 mg/kg+...

Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, VEYS, EM, ...

Healthcare consumption and direct costs of rheumatoid arthritis in Belgium (2005)

WESTHOVENS, R, BOONEN, A, VERBRUGGEN, L, DUREZ, P, DE CLERCK, L, MALAISE, M, ...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, WESTHOVENS, R, DUREZ, P, MALAISE, M, ...

DAS28 is a robust measure of the physician's clinical judgment of response infliximab therapy (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, WESTHOVENS, R, DUREZ, P, ...

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study (2005)

Durez, P., Corluy, L., Veys, E. M., De Clerck, L., Peretz, A., ...

Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients...

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study (2005)

Durez, P., Corluy, L., Veys, E. M., Clerck, L. De, Peretz, A., ...

Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients...

Timing of DAS28 in infliximab therapy: reply (2005)

Durez, P., Corluy, L., Veys, E., De Clerck, L., Peretz, A., ...

Timing of DAS28 in infliximab therapy: reply (2005)

Durez, P., Corluy, L., Veys, E., De Clerck, L., Peretz, A., ...

Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease (2004)

Putzeys, V, Collette, J, De Vos, M, ...

BACKGROUND: Crohn's disease is associated with low bone mineral density and altered bone metabolism. AIM: To assess the evolution of bone metabolism in Crohn's disease patients treated with...

A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis (2004)

KIRWAN, JR, HALLGREN, R, Mielants, Herman, WOLLHEIM, F, BJORCK, E, PERSSON, T, ...

Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease (2004)

FRANCHIMONT, N, PUTZEYS, V, COLLETTE, J, VERMEIRE, S, RUTGEERTS, P, De Vos, Martine, ...

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism (2002)

De Vos, M, Pescatore, P, ...

BACKGROUND: Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease respond to infliximab treatment. The ability or inability to respond seems to persist...

Increased glucose metabolism detected by (18)FDG PET imaging in unsuspected extra-temporal vessels locations of Horton's disease. Clinical observations and review of literature (2002)

Belhocine, T, Kaye, O, Delanaye, P, Corman, V, Baghaie, M, Deprez, M, ...

Increased glucose metabolism detected by (18)FDG PET imaging in unsuspected extra-temporal vessels locations of Horton's disease. Clinical observations and review of literature.

Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: Effects of treatment with cyclosporin A (Neoral (R)) (2002)

Vanderborght, A, De Keyser, F, De Backer, M, Malaise, M, Baeten, D, ...

Objective. To study T cell receptor (TCR) repertoire changes in synovial membrane over a 16 week period in patients with early rheumatoid arthritis (RA); and to study the influence of cyclosporin A...

Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: Effects of treatment with cyclosporin A (Neoral (R)) (2002)

Vanderborght, A, De Keyser, F, De Backer, M, Malaise, M, Baeten, D, ...

Objective. To study T cell receptor (TCR) repertoire changes in synovial membrane over a 16 week period in patients with early rheumatoid arthritis (RA); and to study the influence of cyclosporin A...

A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. (2002)

LOUIS, E, VERMEIRE, S, RUTGEERTS, P, De Vos, Martine, VAN GOSSUM, A, PESCATORE, P, ...

Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: Effects of treatment with cyclosporin A (Neoral (R)). (2002)

VANDERBORGHT, A, De Keyser, Filip, GEUSENS, P, DE BACKER, M, MALAISE, M, Baeten, Dominique, ...

Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: Effects of treatment with cyclosporin A (Neoral (R)) (2002)

De Keyser, F, Geusens, P, De Backer, Manu; U0039058, Malaise, M, Baeten, D, ...

Objective. To study T cell receptor (TCR) repertoire changes in synovial membrane over a 16 week period in patients with early rheumatoid arthritis (RA); and to study the influence of cyclosporin A...

WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis (2001)

Emery, P., Appelboom, T., Breedveld, F. C., Edelmann, E., Kekow, J., ...

Severe adult rheumatoid arthritis is a cause of progressive disability and increased mortality across Europe. A cure for the disease remains elusive, but control of symptoms and maintenance of...

Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment

Ribbens, C, Martin, Y, Franchimont, N, Kaiser, M, Jaspar, J, Damas, P, ...

Objective: To determine matrix metalloproteinase-3 (MMP-3) serum levels in patients with rheumatic diseases and to study the relation between MMP-3 and C reactive protein (CRP) levels.

Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

Rau, R, Breedveld, F, Kalden, J, Malaise, M, ...

Objectives: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in disease modifying antirheumatic drug (DMARD) refractory patients with longstanding, active rheumatoid...

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

Atkins, C, Malaise, M, Sany, J, Russell, A, ...

Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed.

A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis

Kirwan, J, Hallgren, R, Mielants, H, Wollheim, F, Bjorck, E, Persson, T, ...

Objectives: To compare budesonide, a locally acting glucocorticoid with minimal systemic exposure, with conventional glucocorticoid treatment and placebo in rheumatoid arthritis.

Reactivity of human anti-alpha-galactosyl IgG antibody with alpha(1-->3)-linked galactosyl epitopes exposed on basement membranes and on glomerular epithelial cells: an in vitro and in vivo study in the mouse.

Vecchi, M L, Davin, J C, Castronovo, V, Foidart, J M, Malaise, M, Foidart, J B, ...

Anti-alpha-galactosyl antibody (a-Gal Ab) is a human natural antibody belonging to the IgG class, found in high titres in all normal sera regardless of blood group, and specifically recognizing alpha...

Increased expression of receptor activator of NF-κB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients

FRANCHIMONT, N, REENAERS, C, LAMBERT, C, BELAICHE, J, BOURS, V, MALAISE, M, ...

Crohn's disease (CD) is associated with low bone mass due to chronic inflammation and other factors. Receptor activator of NF-κB ligand (RANKL), its receptor RANK and its decoy receptor...

Tumour necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans

Louis, E, Franchimont, D, Piron, A, Gevaert, Y, Schaaf-Lafontaine, N, Roland, S, ...

TNF-α is involved in infectious and immuno-inflammatory diseases. Different individuals may have different capacities for TNF-α production. This might determine a predisposition to develop some...

Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease

Louis, E, Ribbens, C, Godon, A, Franchimont, D, De Groote, D, Hardy, N, ...

Inflammatory bowel diseases (IBD) are characterized by a sustained inflammatory cascade that gives rise to the release of mediators capable of degrading and modifying bowel wall structure. Our aims...

EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: Prevalence of inflammation in osteoarthritis

D'Agostino, M, Conaghan, P, Le Bars, M, Baron, G, Grassi, W, Martin-Mola, E, ...

Objectives: To assess the prevalence of inflammation in subjects with chronic painful knee osteoarthritis (OA), as determined by the presence of synovitis or joint effusion at ultrasonography (US);...

EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 2: Exploring decision rules for clinical utility

Conaghan, P, D'Agostino, M, Ravaud, P, Baron, G, Le Bars, M, Grassi, W, ...

Background: Synovial inflammation (as defined by hypertrophy and effusion) is common in osteoarthritis (OA) and may be important in both pain and structural progression.